Glycine, glycylglycyl-L-serylglycyl- | 51325-29-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glycine, glycylglycyl-L-serylglycyl-
• 英文别名: 2-[[2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetic acid
• CAS: 51325-29-2
• 化学式: C₁₁H₁₉N₅O₇
• 分子量: 333.3
• InChiKey: MGHPRJXUGLYWAA-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.7
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  200
• 氢给体数：
  7
• 氢受体数：
  8

文献信息

• Anti-B7-H4 antibodies and methods
  申请人：NantBio, Inc.

  公开号：US10814011B1

  公开（公告）日：2020-10-27

  Compositions, methods, and uses of recombinant B7-H4 protein or binding motifs to B7-H4 protein that can reduce the immune suppression effect of B7-H4 in relation to T cell activation, proliferation, and conversion. Preferably, the recombinant B7-H4 protein has a plurality of mutations in N-glycosylation residue to reduce its inhibitory effect to T cell activation and proliferation. The recombinant protein having binding motifs to B7-H4 protein preferably includes a binding motif to IgC domain and another binding motif to IgV domain such that the immune-suppressive effects by two Ig-like domains are concurrently reduced.

  重组 B7-H4 蛋白或 B7-H4 蛋白结合基团的组成、方法和用途，可降低 B7-H4 对 T 细胞活化、增殖和转化的免疫抑制作用。优选地，重组 B7-H4 蛋白的 N-糖基化残基有多个突变，以降低其对 T 细胞活化和增殖的抑制作用。具有与 B7-H4 蛋白结合基团的重组蛋白最好包括一个与 IgC 结构域结合的基团和另一个与 IgV 结构域结合的基团，从而同时降低两个 Ig 样结构域的免疫抑制作用。
• mRNA display antibody library and methods
  申请人：NantBio, Inc.

  公开号：US11034951B2

  公开（公告）日：2021-06-15

  Compositions, methods and uses of a recombinant virus and/or recombinant viral vector encoding a distinct antibody or antibody fragment generated from high-diversity nucleic acid library are presented. Preferably, the recombinant virus is genetically modified, low immunogenic virus, for example, an E2b-deleted adenovirus. The high-diversity nucleic acid library comprises or is derived from (1) a VH-CDR1/2 sub-library, (2) a plurality of VH-CDR3 sub-libraries, and (3) a VL sub-library, each of which comprises a plurality of members. Preferably, each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions. In an especially preferred embodiment, at least portions of at least two members of the VH-CDR1/2 sub-library, the plurality of VH-CDR3 sub-libraries, and the VL sub-library are recombined to form an expression library member in an expression library, where each member of the expression library encodes a distinct antibody or antibody fragment.

  本文介绍了一种重组病毒和/或重组病毒载体的组成、方法和用途，这种病毒和/或重组病毒载体编码由高多样性核酸文库产生的独特抗体或抗体片段。重组病毒最好是经过基因修饰的低免疫原性病毒，例如 E2b 缺失的腺病毒。高多样性核酸文库包括或来源于（1）VH-CDR1/2 子文库，（2）多个 VH-CDR3 子文库和（3）VL 子文库，每个子文库包括多个成员。优选地，子库的每个成员包括至少一个具有多个退化碱基位置的随机盒。在一个特别优选的实施方案中，VH-CDR1/2 子库、多个 VH-CDR3 子库和 VL 子库中至少两个成员的至少部分被重组，以在表达库中形成表达库成员，其中表达库的每个成员编码不同的抗体或抗体片段。
• MRNA display antibody library and methods
  申请人：NantBio, Inc.

  公开号：US11015188B2

  公开（公告）日：2021-05-25

  Compositions, methods and uses of high-diversity nucleic acid library that encodes a plurality of antibodies or antibody fragments are presented. The high-diversity nucleic acid library comprises or is derived from (1) a VH-CDR1/2 sub-library, (2) a plurality of VH-CDR3 sub-libraries, and (3) a VL sub-library, each of which comprises a plurality of members. Preferably, each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions. In an especially preferred embodiment, at least portions of at least two members of the VH-CDR1/2 sub-library, the plurality of VH-CDR3 sub-libraries, and the VL sub-library are recombined to form an expression library member in an expression library, where each member of the expression library encodes a distinct antibody or antibody fragment.

  本文介绍了编码多种抗体或抗体片段的高多样性核酸文库的组成、方法和用途。高多样性核酸文库包括或来源于（1）VH-CDR1/2 子文库，（2）多个 VH-CDR3 子文库和（3）VL 子文库，每个子文库包括多个成员。优选地，子库的每个成员包括至少一个具有多个退化碱基位置的随机盒。在一个特别优选的实施方案中，VH-CDR1/2 子库、多个 VH-CDR3 子库和 VL 子库中至少两个成员的至少部分被重组，以在表达库中形成表达库成员，其中表达库的每个成员编码不同的抗体或抗体片段。
• Treatment of hearing impairments
  申请人：——

  公开号：US20020039995A1

  公开（公告）日：2002-04-04

  Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing impairments involving neuronal damage, loss, or degeneration, preferably of spinal ganglion neurons, by administration of a therapeutically effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect, wherein the improvement includes administering a therapeutically effective amount of a trkB or trkC agonist to treat the ototoxicity.

  提供了通过施用治疗有效量的trkB或trkC激动剂，特别是神经营养素，更优选NT-4/5，预防或治疗哺乳动物的听力损伤的组合物和方法。还提供了用于治疗需要施用具有耳毒性副作用的药物的改进组合物和方法，其中的改进包括施用治疗有效量的trkB或trkC激动剂来治疗耳毒性。
• Treatment of balance impairments
  申请人：——

  公开号：US20020169124A1

  公开（公告）日：2002-11-14

  Compositions and methods are provided for prophylactic or therapeutic treatment of balance impairments involving neuronal damage, loss, or degeneration, preferably of vestibular ganglion neurons, in an animal by administration of an effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5

  提供了用于预防或治疗动物平衡障碍的组合物和方法，这些障碍涉及神经元损伤、丢失或变性，最好是前庭神经节神经元的损伤、丢失或变性，通过施用有效量的 trkB 或 trkC 激动剂，特别是神经营养素，更优选 NT-4/5